tbuckley/cabot-search huggingface dataset:
Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or CHOP-Based Chemotherapy +/− Rituximab as a Treatment for PTLD Does No Impair the Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant Recipients with PTLD and 1075 Renal Transplant Controls
Authors: Ulrike Appel, Carl Hinrichs, Petra Reinke, Nina Babel, Hans H Neumayer, Klemens Budde, Martin Dreyling, Ulrich Dührsen, Volker Kliem, Silke Schüttrumpf, Ingeborg A Hauser, Hans G Mergenthaler, Bernd Dörken, Ioannis Anagnostopoulos, Hanno Riess, Ralf Trappe
Journal: Blood (2008)
Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients.
Authors: A. S. Lehmann, A. Egbelakin, S. K. Quinney, L. Li, J. L. Renbarger
Journal: Journal of Clinical Oncology (2010)

9523 Background: This study evaluates the relationship between vinca alkaloid pharmacologic pathway genetic polymorphisms, demographic data, pharmacokinetics, and vincristine-induced peripheral neuropathy (VIPN) in pediatric acute lymphoblastic leukemia (ALL) patients. Pediatric ALL CYP3A5 expressers experience less VIPN and metabolize vincristine (VCR) into its major metabolite M1 at a greater rate than do the non- expressers but significant inter-individual variability remains. We hypothesize that multiple variables contribute to the metabolism of VCR into M1 and the development of VIPN in pediatric ALL patients. Methods: Patients 1-18 years old, with confirmed pre-B ALL diagnosis, who received VCR as part of their treatment regimen were eligible for this trial. Whole blood samples for DNA extraction were collected from enrolled patients (n=130). Subjects were genotyped for polymorphisms in CYP3A4, CYP3A5, MDR1, MAPT, MRP1, and MRP2. VIPN was assessed retrospectively via chart review and graded per the NCI Common Terminology Criteria for Adverse Events, version 3.0. VCR and M1 were quantified in plasma samples collected one hour after administration of VCR using LC-MS/MS. Variables associated with extent of VIPN and plasma concentration were determined using stepwise linear regression (lm) and linear mixed effects models (lme) in R. Results: Of the genotypes examined, the combination of CYP3A5 and MAPT C1428T genotypes best predicted cumulative VIPN over the first year of ALL therapy (p=0.031). MAPT C1428T homozygous variant CYP3A5 non-expressers had the highest cumulative VIPN scores. This combination with age was the most predictive of the proportion of treatment months patients experienced VIPN (p=0.004). M1 plasma concentration at 1 hour was predicted by age (p=0.002) and CYP3A5 genotype (p<0.001) with young CYP3A5 expressers producing the most M1. Conclusions: Age, CYP3A5 and MAPT genotype are important determinants of VIPN. CYP3A5 and age are determinants of M1 formation, indicating that variability in VCR metabolism may impact extent of VIPN. Further evaluation of other potential biomarkers and improvement in clinical assessment of VIPN are needed. No significant financial relationships to disclose.
Release of High Levels of Platelet Factor 4 (PF4) from Platelets Improves Survival after a Lethal Lipopolysaccharide (LPS) Challenge.
Authors: M. Anna Kowalska, Michele P. Lambert, Lubica Rauova, William J. Smith, Shawn A. Mahmud, Mortimer Poncz, Arne Slungaard
Journal: Blood (2006)
A clinical placement program for primary care professionals at a comprehensive cancer centre.
Authors: Michael Jefford, Judy Evans, Linda Nolte, Amanda Piper, Liz Simkiss, Kathryn Whitfield
Journal: Journal of Clinical Oncology (2016)

44 Background: Primary care physicians (PCPs) and primary care nurses (PCNs) are likely to have a critical role in providing care for cancer survivors, especially following the end of cancer treatments. Generalists (PCPs and PCNs) express a need for information and training in post-treatment care. Based on models in other contexts a clinical placement program was developed at a comprehensive cancer centre to determine (1) its feasibility and acceptability, and (2) whether learning needs were met. Methods: Five clinical services (breast, lower gastro-intestinal, urology, skin and melanoma, late effects) participated. The program was advertised to generalists, intending to recruit 5 PCPs and 10 PCNs. Generalists received professional development points and partial reimbursement for lost income through a stipend. Pre-placement educational materials were provided. Participants were interviewed one-on-one pre and post-placement. The relevant human research ethics committee approved all aspects of the project. Results: The program exceeded recruitment goals: 16 PCPs, 12 PCNs and 9 oncologists participated. Generalists rated the placement highly: program learning outcomes entirely (63%) or partially (37%) met; personal learning needs entirely (70%) or partially met (30%); relevance to practice entirely (89%), partially (11%). Consistent themes from interviews: generalists would recommend the program to colleagues and could identify knowledge and skills transfer, however learning was largely by observation, rather than participation. Learning opportunities were skewed toward generalists, rather than oncologists. All participants showed enthusiasm to address the challenges of providing shared care for survivors. Conclusions: A clinical placement program for generalists is feasible and highly regarded. Participants described challenges to providing quality post-treatment shared care, but a willingness to address these. Future programs should consider the learning needs of cancer centre professionals.
Ipatasertib (GDC-0068), a novel Akt inhibitor, synergizes with anti-microtubule chemotherapic agents in human breast cancer cell lines
Authors: C.M. Della Corte, M. Orditura, A. Diana, C. Di Mauro, V. Ciaramella, F. De Vita, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2016)
The oncogenic role of FGFR1 depends on the molecular context
Authors: A. Quintanal, I. Ferrer, L. Ojeda-Márquez, Á Marrugal, R. Suarez, L. García-Redondo, A. Carnero, L. Paz-Ares, S. Molina-Pinelo
Journal: Annals of Oncology (2016)
The Role of Iron in the Cytotoxicity Induced in Hematopoietic Malignant Cell Lines by an Anti-Transferrin Receptor IgG3-Avidin Fusion Protein and Gambogic Acid.
Authors: Elizabeth Ortiz-Sanchez, Tracy R. Daniels, Gustavo Helguera, Otoniel Martinez-Maza, Benjamin Bonavida, Manuel L. Penichet
Journal: Blood (2007)
A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).
Authors: C Foster Matthew, Chirag Amin, Peter M Voorhees, Hendrik W. Van Deventer, Kristy L. Richards, Anastasia Ivanova, Jennifer Whitman, Thomas C. Shea
Journal: Blood (2009)
Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd.
Authors: Shoba Amarnath, Carliann M Costanzo, Jason Foley, Jacopo Mariotti, Daniel M Konecki, ANu Gangopadhyay, Michael Eckhaus, Susan Wong, Bruce Levine, Carl H. June, Daniel H. Fowler
Journal: Blood (2009)
Comment on Epidermal Hyperplasia and Tumor Promotion: Reply
Authors: T. J. Slaga
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Comment on Epidermal Hyperplasia and Tumor Promotion: Reply Get access T. J. Slaga, Ph.D. T. J. Slaga, Ph.D. Oak Ridge National Laboratory, Post Office Box Y OakRidge, Tennessee 37830 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Pages 299–300, https://doi.org/10.1093/jnci/59.2.299-a Published: 01 August 1977
PC or PCV? That is the question: A retrospective review of primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.
Authors: Courtney C. Webre, Nicole A. Shonka, John Frederick De Groot
Journal: Journal of Clinical Oncology (2014)

2046 Background: While procarbazine, CCNU and vincristine (PCV) has been shown to be efficacious in the treatment of anaplastic oligodendroglial tumors (AOT), the question of whether procarbazine and CCNU (PC) alone is sufficient still exists, since vincristine has been argued to add toxicity with little if any clinical benefit. This retrospective study was designed to provide initial insight into the comparison of PC with and without vincristine. Methods: Using the Brain Tumor Center historical database, we queried patients diagnosed with (AOT) treated at MD Anderson Cancer Center from June 1, 1993 through October 13, 2009. Patients were eligible if they had been diagnosed with a primary AOT and were subsequently treated with either PC or PCV at some point in the treatment regimen. A total of 120 patients were included in the study population, with 97 patients included in the primary analysis of treatment before first progression. Results: Initial treatment included radiation and chemotherapy (80.4%), chemotherapy alone (18.6%), or radiation alone (1.0%). Overall survival did not differ with initial treatment. 21 patients (21.6%) received PC during primary treatment, while 76 patients (78.4%) received PCV. 11 patients reported neurotoxicity in the PCV arm (defined as dysautonomia, peripheral neuropathy and ataxia), compared with none in the PC arm. Of the 97 patients included in the analysis, 45 were alive at last contact with a median follow-up of 9.9 years. The median overall survival (OS) time was 6.5 years (95% CI: 4.8-16.7 years). OS was significantly associated with KPS within one month of diagnosis (p=0.002) but not with age (p=0.26). There were 63 patients with disease progression or death, and the median progression-free survival (PFS) was 2.9 years (95% CI: 2.0-6.3 years). There was no difference between the two groups in OS (p=0.61) or PFS (p=0.28). Conclusions: Initial therapy with PC vs. PCV achieved comparable results with a median follow-up of 9.9 years. There was no difference in dose reductions although neurotoxicity was more frequent with vincristine. Further studies with correlative codeletion status are needed.
Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma.
Authors: M. S. Carlino, C. A. Saunders, V. Gebski, A. M. Menzies, B. Ma, P. F. Lebowitz, R. Kefford, G. V. Long
Journal: Journal of Clinical Oncology (2011)

8539 Background: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is commonly used to assess metabolic response to signalling pathway inhibitors in cancer. Little is known about the prevalence and clinical significance of FDG-PET heterogeneity. We investigated the intrapatient heterogeneity of FDG-PET response in metastatic melanoma treated with GSK2118436, an inhibitor of oncogenic mutant BRAF kinase, to determine if heterogeneity predicts clinical outcome. Methods: All patients (pts) with BRAF mutant metastatic melanoma and ≥2 PET avid lesions treated in the BRF112680 Phase I trial of GSK2118436 at a single institution (n=23) were included. Metabolic response was assessed by comparing pre-treatment FDG-PET scans with scans at day 15 of GSK2118436 administration. Metabolic response was assessed 1) qualitatively and 2) according to the European Organization for Research and Treatment of Cancer (EORTC) criteria. Qualitative analysis was the sole method used in those where FDG-PET scans were not performed on the same scanner (n=7). Only lesions with a significant FDG uptake on initial PET/CT or a new FDG avid lesion(s) on follow-up were considered for analysis. Heterogeneity was defined as >10% of lesions with a stable metabolic response or any new or metabolically progressing lesion(s) in the presence of other responding lesions. Results: 26% (n=6) of pts had a heterogeneous FDG-PET response. Median TTP was significantly shorter in those with a heterogeneous vs homogeneous response (3.4 months vs 7.4 months, p=0.027). Age, BRAF mutation genotype, dose, baseline or change in LDH, did not predict for heterogeneity. No relationship was seen between heterogeneity and best RECIST response (p=0.2). Conclusions: Heterogeneous FDG-PET responses are common in metastatic melanoma treated with GSK2118436, and our data suggests heterogeneity is associated with a shorter TTP. Further investigation in larger cohorts is warranted to confirm if FDG-PET heterogeneity is of predictive utility. FDG-PET heterogeneity may predict molecular heterogeneity, and FDG-PET directed biopsies may facilitate investigation into mechanisms of resistance to signal pathway inhibitors.
IL-36 Signaling Facilitates Activation of the NLRP3 Inflammasome and IL-23/IL-17 Axis in Renal Inflammation and Fibrosis
Authors: Hsi-Hua Chi, Kuo-Feng Hua, Yu-Chuan Lin, Ching-Liang Chu, Chih-Yu Hsieh, Yu-Juei Hsu, Shuk-Man Ka, Yu-Ling Tsai, Feng-Cheng Liu, Ann Chen
Journal: Journal of the American Society of Nephrology (2017)

IL-36 cytokines are proinflammatory and have an important role in innate and adaptive immunity, but the role of IL-36 signaling in renal tubulointerstitial lesions (TILs), a major prognostic feature of renal inflammation and fibrosis, remains undetermined. In this study, increased IL-36α expression detected in renal biopsy specimens and urine samples from patients with renal TILs correlated with renal function impairment. We confirmed the increased expression of IL-36α in the renal tubular epithelial cells of a mouse model of unilateral ureteral obstruction (UUO) and related cell models using mechanically induced pressure, oxidative stress, or high mobility group box 1. In contrast, the kidneys of IL-36 receptor (IL-36R) knockout mice exhibit attenuated TILs after UUO. Compared with UUO-treated wild-type mice, UUO-treated IL-36 knockout mice exhibited markedly reduced NLRP3 inflammasome activation and macrophage/T cell infiltration in the kidney and T cell activation in the renal draining lymph nodes. In vitro, recombinant IL-36α facilitated NLRP3 inflammasome activation in renal tubular epithelial cells, macrophages, and dendritic cells and enhanced dendritic cell-induced T cell proliferation and Th17 differentiation. Furthermore, deficiency of IL-23, which was diminished in IL-36R knockout UUO mice, also reduced renal TIL formation in UUO mice. In wild-type mice, administration of an IL-36R antagonist after UUO reproduced the results obtained in UUO-treated IL-36R knockout mice. We propose that IL-36 signaling contributes to the pathogenesis of renal TILs through the activation of the NLRP3 inflammasome and IL-23/IL-17 axis.
A Novel Model of Short Chain Fatty Acid (SCFA)- Mediated up-Regulation of Embryonic/Fetal Globin Genes during Definitive Erythropoiesis.
Authors: Himanshu Bhatia, Jennifer L. Hallock, Lauren E. Sterner, Shay Karkashon, Amrita Dutta, Toru Miyazaki, Ann Dean, Jane Little
Journal: Blood (2008)
Prognostic factors for survival in patients with stage (stg) IV malignant melanoma (MM)
Authors: N. Seetharamu, H. Hamilton, T. Tu, P. Christos, I. Osman, A. C. Pavlick
Journal: Journal of Clinical Oncology (2009)

9072 Background: Prognosis for survival in MM is not uniform with some pts being long-term survivors. Identifying this subset of pts may have implications on surveillance and treatment (tx). Unfortunately, prognostic data available for MM and the utility of AJCC staging in predicting survival is limited. We analyzed prospectively collected data from the NYUCI Interdisciplinary Melanoma Cooperative Group program (IMCG) to identify clinicopathological variables predictive of MM survival. Methods: We identified 185 pts enrolled in the IMCG with MM diagnosed and treated at NYUCI. Demographic, clinical, and tx-related factors were included in the analysis. Kaplan-Meier (KM) survival analysis was used to identify univariate predictors of post-stage IV survival and their independent effect was assessed in a multivariate Cox proportional hazards regression model. Results: Median age at diagnosis (dx) of metastatic MM was 64 years (22–92). Median overall survival: 13.8 months(m) (128 deaths and a median follow up of 18.6 m (4–141) for survivors). Factors identified on univariate analysis at p&lt;0.20 were evaluated in the multivariate model ( table ). Co-morbidities, site and histology of primary melanoma, initial staging, prior loco-regional recurrences, and adjuvant tx of primary melanoma were not associated with MM survival. Univariate analysis also showed significant survival advantage (p value 0.0011) for patients with AJCC stages M1a and M1b (21.6 m and 17.2 m respectively) over those with AJCC stage M1c (9 m). Conclusions: This cohort study of MM identified female gender, nl serum LDH, nl albumin, and solitary organ involvement as independent survival predictors. Patients who received systemic therapy± local measures had survival benefit over those that had surgery and/or radiation alone suggesting a role for systemic treatment in MM. Patients with personal history of another malignancy (n=37) showed a trend towards improved survival. This novel observation needs to be validated and studied further. [Table: see text] No significant financial relationships to disclose.
Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)
Authors: Bradley W. Chipps, William Busse, Allan T. Luskin, Robert S. Zeiger, Benjamin L. Trzaskoma, Noelle M. Griffin, Evgeniya Antonova, Susan L. Limb, Thomas B. Casale
Journal: Journal of Allergy and Clinical Immunology (2017)
193P A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors
Authors: J. Cao, D. Ji, W. Shen, Q. Wang, Y. Liu, D. Lu, I. Sturm, F. Huang, A. Cleton
Journal: Annals of Oncology (2016)
Monitoring JAK3 mRNA Levels in Patients with GVHD after Allogeneic Hematopoietic Stem Cell Transplantation by Real-Time Quantitative PCR.
Authors: Qihui Li, Xin Du, Suxia Geng, Jianyu Weng, Rong Guo, Zesheng Lu, Haizhou Xing
Journal: Blood (2006)
The Mouse Mutation “Thrombocytopenia and Cardiomyopathy” (trac) Is within the ABCG5 Gene: A Single Gene Model for Human Mediterranean Macrothrombocytopenia.
Authors: Leonard D. Shultz, Bonnie L. Lyons, Thomas H. Chase, Roderick Bronson, LeahRae Donahue, Lisa Carney, Bruce Gott, Belinda Harris, Joseph Italiano
Journal: Blood (2007)
Clinical Efficacy of VEL-CTD (Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone) Regimen in Patients with Relapsed or Refractory Multiple Myeloma: A Phase II Study
Authors: Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Kyun Sohn, Ho-Jin Shin, Joo-Seop Chung, Young-Jin Choi, Joon-Ho Moon, Yee-Soo Chae, Jong-Gwang Kim, Jae-Sook Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, the Korean Multiple Myeloma Working Party (KMMWP)
Journal: Blood (2008)
Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.
Authors: Howard Kaufman, Jose Lutzky, Joseph Clark, Kim Allyson Margolin, David H. Lawson, Asim Amin, Frances A. Collichio, Andrew Pecora, Walter John Urba, Kelly L. Bennett, David F. McDermott
Journal: Journal of Clinical Oncology (2013)

9050 Background: MDX010-020 was a phase III comparison of ipilimumab (Ipi), gp100 vaccine or the combination for advanced melanoma. A subset of patients (pts) received other immunotherapy (IM) for advanced disease prior to receiving Ipi, providing the opportunity to evaluate safety and efficacy of Ipi following IM. A prior analysis has shown that pts receiving prior IL-2 had a similar overall survival (OS) to pts who had not received prior IL-2 [Hodi et al NEJM2010]; we now report expanded results for pts receiving any prior IM (interferons and/or interleukin). Methods: Eligible pts (n=676) had unresectable stage III/IV melanoma and were randomized 3:1:1 to q3 wks x 4 doses of Ipi + gp100 or Ipi + placebo or gp100 + placebo. All Ipi doses were 3 mg/kg i.v. OS was retrospectively analyzed for pts receiving any prior IM; immune-related adverse events (irAEs) during induction were evaluated for pts who received any prior IM (322 pts, 48%) and for pts who received prior IL-2 (154 pts, 23%). Results: Demography and OS are summarized below. irAEs of any grade were reported for 60% (Ipi) and 54% (Ipi + gp100) of pts receiving any prior IM. Those receiving prior IL-2 specifically had 73% (Ipi) and 58% (Ipi + gp100) incidence of any grade irAEs. Incidence was similar for those not receiving prior IM or prior IL-2. Diarrhea, rash, and pruritus were the most common events in all groups. Conclusions: Results for OS in this subgroup analysis were similar for both those receiving any prior IM and those who did not receive prior IM and to the overall 020 population. In addition, safety profiles were similar irrespective of prior immunotherapy. Clinical trial information: NCT00094653. [Table: see text]
Nephrotoxicity induced by VEGF-target agents in patients with metastatic renal cell cancer.
Authors: Tomoyuki Kato, Shoko Nakayama, Takafumi Narisawa, Atsushi Yamagishi, Toshihiko Sakurai, Sei Naito, Hisashi Kawazoe, Osamu Ichiyanagi, Vradimir Bilim, Akira Nagaoka, Yoshihiko Tomita
Journal: Journal of Clinical Oncology (2012)

432 Background: A study was undertaken to investigate the association between treatment with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell cancer (mRCC) and nephrotoxicity. Methods: Retrospective data were collected for mRCC patients received VEGF-targeted therapy between January 2005 and December 2010. We investigated renal adverse events and clinically significant increased serum creatinine level in patients who received VEGF target therapy. GFR was estimated with the Modification of Diet in Renal Disease (MDRD) formula. Results: Ninety one patients with mRCC who received sunitinib (n=46), sorafenib (n=38), axitnib (n=9) were included in this analysis. As for renal adverse events, acute renal failure occurred in 1 (2.2%) of 46 sunitinib recipients. Facial edema occurred 17 (37.0%) in sunitinib recipients, 2 (5.3%) of sorafenib recipients, 2 (22.2%) of axitinib recipients. In sunitinib recipients, all of these adverse events observed in ‘off’ period. During administration, gradual and significant increase of serum creatinine was observed in sunitinib recipients compared for sorafenib or axitinib recipients (p= 0.04). Significant decrease of GFR compared for baseline correlated with increase of serum creatinine level developed in ‘on’ period of 6 sunitinib administration cycle (p=0.013), but returned to baseline level after 2weeks cessation. No significant change was observed in serum creatinine level and GFR in patients received other VEGF-target agents. Conclusions: Our data suggest that nephrotoxicity developed in a high percentage of patients on sunitinib compared for sorafenib and axitinib in mRCC patients. Clinicians should observe renal function of sunitinib recipients more carefully in ‘off’ period as well as ‘on’ period.
A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Authors: Elias J. Jabbour, Nicholas J. Short, Xuelin Huang, Abhishek Maiti, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Courtney D DiNardo, Naveen Pemmaraju, Koji Sasaki, Zeev Estrov, Srdan Verstovsek, Farhad Ravandi, Yesid Alvarado, Mikkael A. Sekeres, Rami S. Komrokji, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Darla Miller, Xiao Dong, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2016)
Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.
Authors: Justin P. Kline, Rajiv Swamy, Dezheng Huo, Laura Michaelis, Richard A. Larson, Elizabeth Rich, Wendy Stock, Jody Ulaszek, Amittha Wickrema, Andrew Artz, Maher Albitar, Koen van Besien
Journal: Blood (2005)